SCHEMBL4819019

SCHEMBL4819019

COc1ccccc1C(=O)c1cc(C)ccc1NC(=O)Nc1ncc(Sc2nc(C(=O)O)c[nH]2)s1

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TP53 P04637 1/20 0.44
GAA P10253 1/20 0.44
MAPT P10636 3/20 0.38
SMN1; SMN2 Q16637 3/20 0.38
LMNA P02545 1/20 0.38
HTT P42858 1/20 0.38
ITK Q08881 3/20 0.37
NPC1 O15118 2/20 0.36
RAB9A P51151 2/20 0.36
KMT2A Q03164 4/20 0.36
MEN1 O00255 3/20 0.36
MAPK1 P28482 1/20 0.36
ALDH1A1 P00352 1/20 0.36
TXK P42681 1/20 0.35
JAK3 P52333 1/20 0.35
BTK Q06187 1/20 0.35
KCNMA1 Q12791 1/20 0.35
LTC4S Q16873 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1343486 0.86 TP53 (0.45) TP53GAAMAPTSMN1; SMN2LMNA
SCHEMBL1342456 0.85 TP53 (0.44) TP53GAAMAPTSMN1; SMN2LMNA
SCHEMBL6704338 0.83 TP53 (0.47) TP53GAAMAPTSMN1; SMN2LMNA
SCHEMBL1344127 0.83 TP53 (0.47) TP53GAAMAPTSMN1; SMN2LMNA
SCHEMBL1343844 0.82 TP53 (0.44) TP53GAAMAPTSMN1; SMN2LMNA
SCHEMBL1342625 0.82 TP53 (0.44) TP53GAAMAPTSMN1; SMN2LMNA
SCHEMBL1341796 0.82 TP53 (0.48) TP53GAAMAPTSMN1; SMN2LMNA
SCHEMBL1343208 0.82 TP53 (0.43) TP53GAAMAPTSMN1; SMN2LMNA
SCHEMBL1342953 0.81 TP53 (0.47) TP53GAAMAPTSMN1; SMN2LMNA
SCHEMBL1343462 0.81 TP53 (0.47) TP53GAAMAPTSMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7384967-B2 Aryl carbonyl derivatives as therapeutic agents NOVO NORDISK A/S (DK) 2008-06-10 US disclosed
US-20040122235-A1 Aryl carbonyl derivatives as therapeutic agents VTV THERAPEUTICS LLC 2004-06-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040122235-A1 Aryl carbonyl derivatives as therapeutic agents GCK, GCKR, PDK2 TP53 2961/4885GAA 48/4885MAPT 2678/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.